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Essay
It’s Not How Fat You Are,
It’s What You Do with It That Counts
Samuel Virtue*, Antonio Vidal-Puig* 
T
he spiralling increase in 
obesity rates in the Western 
and developing worlds has 
brought with it a host of related 
metabolic complications including 
diabetes, dyslipidaemia, cardiovascular 
complications, and cancer. Whereas 
obesity itself presents its own 
independent health problems—such 
as sleep apnoea or psychological 
issues—the vast majority of obesity-
related mortality is caused by these 
secondary metabolic complications. 
The link between obesity and such 
complications as insulin resistance is 
well established on a population level 
but poorly understood mechanistically. 
Efforts to tackle the obesity epidemic 
through public health initiatives and 
drugs have so far been notable for their 
lack of success. With little prospect for 
halting the obesity epidemic, treatment 
of its associated diseases becomes of 
paramount importance both for public 
health and associated costs [1]. 
On an epidemiological level, 
there is a strong correlation between 
obesity and diabetes; in fact, for every 
kilogram gained on a population 
level, diabetes rates increase linearly 
[2]. The link between obesity and 
diabetes has led to the assumption 
that the degree of insulin resistance 
in an individual rises in parallel with 
one’s fat mass. However, multiple 
studies have demonstrated that at 
the individual level, the association 
between degree of obesity and 
development of insulin resistance may 
not be so clear cut. Several apparent 
clinical paradoxes appear to contradict 
the direct link between excessive fat 
mass and insulin resistance. First, it is 
well documented that lipodystrophic 
individuals develop severe insulin 
resistance [3,4]. Lipodystrophy is a 
clinical condition that is characterised 
by an inherent failure in adipose 
tissue development and/or function. 
Individuals with lipodystrophy cannot 
accumulate fat and are extremely 
lean, yet they often suffer from 
diabetes, dyslipidaemia, and other 
metabolic complications. Conversely, 
some morbidly obese individuals 
do not present with the Metabolic 
Syndrome (see Glossary) [5–7]. 
Furthermore, the thiazolidinedione 
(TZDs) class of antidiabetic drugs 
are potent stimulators of adipose 
tissue differentiation that have been 
demonstrated to increase body weight 
while also improving insulin sensitivity 
[8]. Resolving these paradoxes depends 
on understanding the mechanistic link 
between obesity and insulin resistance, 
a crucial step toward developing 
rational treatments for diseases such 
as type 2 diabetes. In this Essay, we 
discuss the concept of adipose tissue 
expandability and how it can enhance 
our understanding of obesity-related 
metabolic disease by focussing on type 
2 diabetes.
The adipose tissue expandability 
hypothesis states that the capacity of 
an individual to expand their fat mass 
to store lipid is a more important 
determinant of obesity-associated 
metabolic problems than the absolute 
amount of adipose tissue an individual 
possesses. When an individual reaches 
a point where they cannot expand 
their adipose tissue any further, usually 
when they are already obese, then they 
present with metabolic complications 
due to ectopic deposition of excess lipid 
in non-adipose organs such as liver, 
muscle, and pancreatic β cells.  Ectopic 
deposition of lipids in organs other 
than adipose tissue is believed to cause 
insulin resistance via lipid-induced 
toxicity, or lipotoxicity (see Glossary). 
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Box 1. Theories of How Obesity Causes Insulin Resistance
The Adipokine Hypothesis
Obesity leads to an alteration in the profile of hormones secreted by adipose tissue 
(adipokines). In the obese state, adipose tissue secretes proportionally more adipokines 
that cause insulin resistance and fewer that promote insulin sensitivity.
The Inflammation Hypothesis
Obesity is associated with an increase in adipocyte secretion of chemokines, which 
promote macrophage infiltration. In addition to increased macrophage infiltration,
obesity is also associated with increased macrophage activation. Activated 
macrophages produce cytokines that can negatively impact on insulin sensitivity. 
The Adipose Tissue Expandability Hypothesis
Adipose tissue has a limited maximal capacity to increase in mass, which is determined 
on an individual basis by environmental and genetic factors. When an individual reaches 
their adipose tissue expansion limit, then lipid can no longer be stored appropriately 
in adipose tissue. Lipid that is not stored in adipose tissue is deposited in non-adipose 
tissue organs such as liver and muscle and causes insulin resistance by a lipotoxic
mechanism.
Essays articulate a specific perspective on a topic of 
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The adipose tissue expandability 
hypothesis suggests that the insulin 
resistance found in lipodystrophic 
and obese individuals is caused by 
the same pathogenic mechanism of 
impaired adipose tissue expansion 
capacity, even if the underlying cause 
and degree of impairment in adipose 
tissue expansion may be very different. 
While the idea that lean and very 
obese people may develop insulin 
resistance through the same pathogenic 
paradigm of exhaustion of adipose 
tissue expandability is controversial, 
it is actually well supported in rodent 
models. 
Lessons from Rodent Models
Rodent models with impaired adipose 
expandability. Several mouse studies 
have demonstrated that defective 
adipose tissue function causes severe 
insulin resistance [9,10]. The A/
Zip fatless mouse and the adipose-
nSREBP1c TG mouse both have 
impaired adipogenesis, which results in 
a lipodystrophic animal. Both mouse 
models demonstrate that functional 
adipose tissue is necessary to maintain 
normal carbohydrate and lipid 
metabolism. However, the majority 
of type 2 diabetic individuals are not 
lipodystrophic but are actually obese. 
Models of murine lipodystrophy do 
not help to answer whether limited or 
exhausted adipose tissue expansion can 
cause metabolic complications in an 
obese state, or whether it is exclusively 
a phenomenon associated with 
lipodystrophy.
To test if the adipose tissue 
expandability hypothesis can be 
applied to obesity-induced diabetes, 
it is necessary to investigate obese 
mouse models with subtle reductions 
in adipose tissue expansion. Two 
recent mouse studies [11,12] have 
demonstrated that even in overweight 
or obese mice, a genetic limit 
on adipose tissue expansion can 
exacerbate insulin resistance. The 
ob/ob mouse model, which lacks the 
hormone leptin, is extremely obese 
and insulin resistant. According 
to the adipose tissue expandability 
hypothesis, subtly limiting expansion 
of adipose tissue in the ob/ob mouse 
should increase the severity of 
insulin resistance while decreasing 
fat mass. This concept is exemplified 
by the PLO mouse, which carries 
a dominant negative mutation in 
the pro-adipogenic transcription 
factor PPARγ on an ob/ob genetic 
background. Interestingly, PLO mice 
become much more insulin resistant 
than ob/ob controls do, yet they have 
14% less adipose tissue [11]. Despite 
only a subtle reduction in total fat 
mass compared to ob/ob controls, the 
severity of the insulin resistance found 
in the PLO mouse supports the idea 
that impaired adipose expansion may 
cause insulin resistance in the context 
of obesity. 
An obese but insulin-sensitive mouse 
model. Based on the adipose tissue 
expandability hypothesis, it should be 
possible to become massively obese 
without metabolic complications, 
so long as new adipose tissue can be 
made. Until recently there was no 
mouse model of such a state. The 
recent publication by Kim et al. [13] 
of a mouse overexpressing adiponectin 
in adipose tissue on an obese ob/
ob background—the AdTG-ob/ob 
mouse—provides the first example of a 
mouse with apparently limitless adipose 
tissue expandability. Despite having a 
body weight that is 50% greater than 
an ob/ob mouse, the AdTG-ob/ob 
mouse remains insulin-sensitive with 
no ectopic deposition of fat in liver 
[13]. Of note, the majority of the 
adipose tissue gained in the AdTG-ob/
ob mouse is stored in subcutaneous 
depots, which in human studies have 
been shown to be far less detrimental 
to metabolic health than visceral 
adipose tissue stores. Thus, the AdTG-
ob/ob mouse is a dramatic example of 
the power of increasing adipose tissue 
expandability to prevent metabolic 
complications.
Evidence from Humans
Assaying adipose tissue expandability 
in humans is far more difficult than 
in mice; however, some indirect 
evidence does support the concept 
that once adipose tissue capacity for 
lipid storage is exhausted, metabolic 
complications ensue. Evidence for 
a role for adipose tissue in lipid 
homeostasis comes from studies of 
human adipose tissue function in lean 
and obese humans. These studies 
showed that adipose tissue from obese 
individuals was unable to appropriately 
take up lipids in the postprandial state 
and that insulin did not impair fatty 
acid release as efficiently as in lean 
individuals, suggesting that failure in 
lipid buffering in adipose tissue is also a 
result of excessive expansion of adipose 
tissue. The failure to buffer lipid 
appropriately in obese individuals leads 
to elevated fatty acids and triglycerides, 
producing a lipotoxic lipid profile that 
we believe is a fundamental pathogenic 
mechanism leading to the Metabolic 
Syndrome. One possible explanation 
for this buffering failure is that the 
adipose tissue has become saturated, or 
reached the limit of its storage capacity, 
in obese individuals [14]. 
The adipose tissue expandability 
hypothesis is further supported 
by studies that have used TZDs 
to treat non-alchoholic fatty liver 
disease (NAFL) and non-alcoholic 
Glossary
The Metabolic Syndrome: A collection of risk factors for cardiovascular disease that 
cluster together at a higher rate than can be explained by chance. The Metabolic 
Syndrome has multiple definitions, but all encompass components of obesity, 
hypertension, dyslipidaemia, and insulin resistance/diabetes. For a comprehensive 
review see [35].
Lipotoxicity: The process by which inappropriate lipid deposition in organs other 
than adipose tissue causes adverse affects on cellular metabolism, most notably insulin 
action. Specific lipids such as ceramides and diacylglyerides may be more toxic than 
other lipid species such as triacylglycerides.
White Adipose Tissue: The body’s primary long-term energy store, white adipose 
tissue, is also responsible more acutely for whole-organism lipid homeostasis and is an 
important endocrine organ producing many adipokines. White adipose tissue can be 
subdivided into two principal forms based on anatomical location. 
Subcutaneous (SC) White Adipose Tissue is located underneath the skin but outside 
the abdominal cavity. In terms of whole-organism metabolic sensitivity, SC adipose 
tissue is considered either beneficial or at worse inert. 
Visceral White Adipose Tissue is located within the abdominal cavity and has been 
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steatohepatitis (NASH). These studies 
have demonstrated excellent efficacy 
of TZDs in terms of reduced hepatic 
lipid content. Interestingly, TZDs 
promote adipose tissue expansion and, 
in multiple studies, lead to weight gain. 
As increased body mass index (BMI) 
is a risk factor for NASH and NAFL, it 
is striking that these potent lipogenic 
agents actually reduce hepatic lipid 
accumulation [15,16]. The efficacy of 
TZDs appears even more contradictory 
when considering their molecular 
mechanism. In addition to their 
effects on body weight, TZDs might be 
expected to directly increase liver lipid 
content by activating PPARγ. Many 
of the genes involved in both lipid 
uptake (such as lipoprotein lipase) 
and de novo fatty acid biosynthesis, 
such as fatty acid synthase and acetyl-
CoA carboxylase, are up-regulated by 
PPARγ. Thus the coordinate activation 
of lipid uptake and lipid biosynthesis by 
PPARγ would be expected to directly 
increase hepatic lipid deposition 
(steatosis) [17, 18]. However, the 
adipose tissue expandability hypothesis 
explains how TZDs can be beneficial 
for NASH; since increasing the capacity 
of adipose tissue to store fat allows 
repartitioning of lipid from liver 
back to adipose tissue and therefore 
ameliorates the disease state.
Relationship to Other Hypotheses 
as to How Obesity Causes Diabetes
The adipose tissue expansion 
hypothesis should be considered one of 
several major hypotheses to explain the 
link between obesity and the Metabolic 
Syndrome (see Box 1). Perhaps the 
two most well-considered alternative 
hypotheses emerge from characterizing 
obesity as a low-grade inflammatory 
state and adipose tissue as an endocrine 
organ [19]. It has been suggested that 
the action of cytokines such as Tnf-α 
and IL6, which are increased in adipose 
tissue in an obese state, leads to insulin 
resistance. Both Tnf-α and IL6 cause 
insulin resistance within adipose tissue 
[20]. The hypothesis that obesity is a 
generalised low-grade inflammatory 
state does not necessarily contradict the 
adipose tissue expandability hypothesis; 
in fact, the adipose tissue expandability 
hypothesis may help to explain how 
obesity leads to inflammation. In 
humans, obesity correlates well with an 
increase in adipocyte size, which fits 
with a failure to recruit new adipocytes 
to expand adipose tissue depots. Skurk 
et al. [21] demonstrate that large 
adipocytes secrete proportionally 
more pro-inflammatory cytokines 
than anti-inflammatory cytokines 
when compared to small adipocytes, 
and crucially also secrete more 
chemoattractants associated with 
macrophage infiltration than smaller 
adipocytes. Furthermore, free fatty 
acids (FFAs), which are increased 
when adipose tissue fails to store 
lipid appropriately, have also been 
demonstrated to directly activate 
macrophages [22]. Thus, a failure in 
adipose tissue expansion may cause 
a “double whammy” of macrophage 
recruitment and activation, causing 
a localised and potentially systemic 
inflammatory state. Other pathogenic 
mechanisms related with insulin 
resistance include endoplasmic 
reticular (ER) stress and the effects of 
reactive oxygen species (ROS). Again, 
both ER stress and ROS are induced by 
FFA in cell models [23,24]. 
The second major hypothesis 
regarding how obesity leads to 
diabetes regards the role of adipose 
tissue as an endocrine organ. Adipose 
tissue is known to secrete multiple 
hormones, of which leptin is perhaps 
the most famous. Leptin was cloned 
in 1994 (and has subsequently been 
demonstrated to play important 
roles in the control of body weight 
and insulin sensitivity). Over the 
past 14 years, many more adipokines 
have been identified including pro-
insulin sensitising adipokines such 
as adiponectin and adipokines that 
have been implicated in causing 
insulin resistance, such as visfatin, 
retinol binding protein 4, and 
resistin. As discussed above, adipose 
tissue can also secrete chemokines 
and cytokines. The idea that obesity 
leads to altered adipokine profiles 
that can subsequently cause systemic 
insulin resistance is well supported. 
Again, the adipokine hypothesis is not 
contradictory to the adipose tissue 
expandability hypothesis. Larger 
adipocytes found in the obese state 
have altered profiles of adipokine 
secretion. Furthermore, insulin 
resistance can cause alterations in 
adipokine secretion; for example, 
4-month-old ob/ob mice have far 
less adiponectin than wild-type 
littermates do [11]. The data regarding 
adiponectin levels in ob/ob mice would 
suggest that impaired adipose tissue 
expansion may cause insulin resistance 
and then affect adipokine levels. 
Conversely adipokines themselves 
may modulate capacity for adipose 
tissue expansion. For instance, the 
adiponectin Ad-TG mouse model 
commented on above is a mouse model 
overexpressing an adipokine that 
has greatly increased adipose tissue 
expansion capacity [13]. 
The Relative Contribution of 
Visceral versus Subcutaneous 
Adipose Tissue
So far, this Essay has discussed adipose 
tissue in general terms; however, in 
humans, there are distinct differences 
between adipose tissue depots 
dependent on their location. Different 
adipose tissue depots have distinct gene 
expression profiles [25]. Furthermore, 
in humans, visceral adiposity is strongly 
associated with increased metabolic 
risk, whereas subcutaneous adipose 
tissue is not associated with metabolic 
complications and may even be 
protective [26]. The reason for the 
beneficial effects of subcutaneous 
adipose tissue compared to visceral 
adipose tissue is unclear; however, it 
has been suggested that the proximity 
of visceral adipose tissue to the 
portal vein may allow visceral adipose 
tissue to exert more direct metabolic 
effects on the liver. Although the 
proximity of visceral adipose tissue 
to the liver suggests that it may have 
a disproportionate metabolic effect 
on this organ, even in the obese state, 
over 70% of FFA that are delivered 
to the liver are non-viscerally derived 
[27]. If, as we believe, a failure in 
FFA buffering is key component 
of the Metabolic Syndrome, then a 
failure in subcutaneous adipose tissue 
expandability resulting in a failure in 
SC lipid buffering would be expected 
to exert more severe metabolic effects 
than failure in visceral adipose tissue 
expansion. Importantly, a net result of 
maintained visceral adipose expansion 
with a failure in subcutaneous 
adipose tissue expansion would be a 
relative increase in visceral adiposity 
associated with worsened metabolic 
complications.
Evidence to support the concept 
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tissue expansion capacities comes 
from studies demonstrating that 
preadipocytes from subcutaneous 
depots differentiate more rapidly than 
those from omental depots and are 
more responsive to TZDs [28,29]. The 
increased adipogenic potential of the 
subcutaneous depot, when compared 
to the visceral depot, is in good 
accordance with the adipose tissue 
expandability hypothesis. In other 
words, metabolically better adipose 
tissue has greater expansion capacity 
than metabolically detrimental adipose 
tissue.
Although the different metabolic 
properties of visceral and subcutaneous 
fat may be related to the anatomical 
location of the fat depots, there is 
some evidence to suggest that there 
may be intrinsic cell-autonomous 
differences between subcutaneous and 
visceral adipose tissue. Perhaps the 
most compelling evidence for intrinsic 
metabolic properties of subcutaneous 
and visceral adipose tissue depots 
come from the work of Tran et al., 
demonstrating that transplanting 
subcutaneous fat into the abdominal 
cavity of mice improved the metabolic 
profile when compared to either visceral-
to-visceral fat transplants, visceral-
to–subcutaneous, or subcutaneous-to-
visceral transplants [30]. 
A final aspect regarding different 
adipose tissue depots is why some 
individuals develop increased adipose 
tissue in abdominal depots and others 
in visceral depots. It is likely that 
the interactions between intrinsic 
properties of the depots [31] coupled 
to altered levels of hormones such 
as cortisol, growth hormone, sex 
hormones, and insulin all have a part 
to play [32], but more research into 
this aspect is necessary. 
The Concept of a Metabolic Set 
Point
Although epidemiologically the risk 
of diabetes, for example, increases 
linearly with increased body weight, the 
adipose tissue expandability hypothesis 
suggests that this may not be the 
case in an individual. Rather, once 
an individual reaches their maximal 
adipose tissue mass, then metabolic 
complications ensue, suggesting that 
individuals would go from metabolically 
normal to metabolically compromised 
in a relatively small weight window 
(Figure 1A). When averaging effects 
of a large number of individuals, this 
could still result in a linear relationship 
between weight gain and reduction 
in insulin sensitivity (Figure 1B). 
Although the model presented above 
is an oversimplification (obesity is 
not normally distributed across the 
population), it does demonstrate 
how individuals can have dramatically 
different metabolic responses to an 
idealised population. While the concept 
of a metabolic set point is an attractive 
idea, it remains to be validated. 
Future Areas of Investigation
The concept that the primary 
mechanism linking obesity to metabolic 
complications is a failure in the 
capacity of adipose tissue to expand 
to accommodate excess nutrients 
has several clinical and scientific 
implications. Scientifically, it creates a 
unified framework to help to explain 
how diabetes can occur in both obese 
and lipodystrophic states. It also 
integrates explanations of how changes 
in lipid handling and adipocyte size 
may interact to lead to inflammation, 
dyslipidaemia, and ultimately to 
diabetes. However, further work 
remains to validate the adipose tissue 
expandability hypothesis and how it 
may relate obesity to diabetes. 
The recent study of Spalding et 
al. [33] demonstrates that adipocyte 
number in the obese, though higher 
than in lean individuals, remains 
static in later life, suggesting an 
individualised maximum threshold for 
adipose tissue expansion. Furthermore 
alterations in adipose tissue mass in 
adult life involve changes in adipocyte 
size, rather than number. This study 
does not investigate whether adipocyte 
number and formation correlated 
with metabolic complications rather 
than just obesity per se. Crucially, 
during childhood and early adulthood, 
adipocyte number does increase 
dramatically; and intriguingly, this 
increase occurs earlier in the obese 
than in the lean. These processes 
that regulate adipocyte hyperplasia 
in early life need to be determined 
and could potentially provide new 
targets for the treatment of obesity-
associated metabolic complications. 
It is important to note that this study 
was only concerned with people who 
were obese from childhood and that 
adipocyte number may be plastic in the 
case of adult-onset obesity.
The finding that adipocyte number 
is stabilized in adults raises many 
questions about how adipocyte 
formation and life span are regulated. 
If birth and death rates of adipocytes 
are maintained so closely, then there 
must be a homeostatic mechanism that 
allows the control of birth and death 
of adipocytes. But how is the formation 
of new adipocytes regulated? Is it at the 
level of commitment of mesenchymal 
stem cells to preadipocytes, 
preadipocyte hyperplasia, or 
differentiation of preadipocytes to 
mature adipocytes? Clearly a large 
number of questions regarding how 
adipose tissue plasticity is regulated 
remain, and understanding these 
processes will be essential if new drugs 
that target adipose tissue expandability 
are to be developed. 
Clinically, the adipose tissue 
expandability hypothesis has several 
implications. First, it explains how 
pharmacological agents that promote 
adipose tissue expansion may be 
suitable for the treatment of a variety 
of disorders, including diabetes, 
NASH, NAFL, and most recently 
dyslipidaemia. Studies demonstrating 
that TZDs may be suitable for the 
treatment of a wide variety of metabolic 
disorders beyond diabetes have 
unfortunately coincided with concerns 
over the safety of this class of drugs, 
stressing the need for new drugs that 
target adipose tissue expansion. 
Finally, the adipose tissue 
expansion hypothesis may allow for 
the design of better obesity treatment 
doi:10.1371/journal.pbio.0060237.g001
Figure 1. Insulin Sensitivity
(A) Diagram showing the different models 
of how weight loss affects insulin sensitivity 
within an individual. (B) Diagram showing how 
multiple individuals with sigmoid responses 
in insulin sensitivity can add to form a linear 
alteration in insulin sensitivity across a 
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regimes, particularly with respect to 
personalised weight loss programs. 
If there is a “set point” for body 
weight and adipose tissue expansion 
beyond which an individual becomes 
metabolically compromised, then 
tailoring a weight loss program to an 
individual’s threshold of metabolic 
complications, rather than to general 
therapeutically-unachievable targets 
based on population studies, may result 
in better compliance and therefore 
treatment efficacy [34].  
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